![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Abbott’s Neuropathic Pain Blocker Cleared for Marketing
Abbott’s Neuropathic Pain Blocker Cleared for Marketing
![abbott-logo.gif](https://www.fdanews.com/ext/resources/test/Drug-Images/abbott-logo.gif?t=1614806228&width=430)
November 16, 2018
The FDA and EU have both cleared Abbott’s DRG Invisible Trial system for marketing, a device designed to help people suffering from neuropathic pain.
The device targets the dorsal root ganglion (DRG), a nerve structure near the spinal cord that transmits chronic pain to the nervous system.
By transmitting electrical pulses through a thin wire placed in the spinal column near the DRG, the system blocks pain signals from reaching the nervous system.
Upcoming Events
-
21Oct